Medical Science Liaison, Endocrinology – NY Metro Region

Remote

Apply with AI Apply

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, HealthcareIndustries

Requirements

Candidates must possess an advanced degree in medical science (MD, PhD, PharmD, NP, or PA) and have at least 7 years of MSL experience, with a strong preference for therapeutic area expertise in endocrinology. A clinical science degree is required, along with strong business acumen and knowledge of drug development processes. Excellent project management, interpersonal, and communication skills are essential, as is a valid driving record. Applicants must be currently authorized to work in the United States.

Responsibilities

The Medical Science Liaison will engage in scientific discussions with thought leaders and healthcare professionals to build knowledge and advocacy for Cushing's syndrome and Corcept's products. Responsibilities include providing scientific presentations, developing relationships with medical community stakeholders, responding to medical inquiries, generating scientific content, attending scientific events, and critically reviewing scientific literature. The role also involves capturing and reporting insights from the medical community, supporting clinical trials and publications, and maintaining high standards of scientific and clinical expertise. Significant travel (70%) is required.

Skills

Endocrinology

Cortisol Modulators

Glucocorticoid Receptor

Cushing's Syndrome

Medical Affairs

Scientific Presentations

Educational Programs

Medical Community Engagement

Medical Inquiries

Clinical Acumen

Thought Leader Engagement

Healthcare Professional Communication

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free